Dimerix (ASX:DXB)
We spoke with Dr. Nina Webster, CEO of Dimerix (ASX: DXB), about the company’s encouraging interim results in the Phase 3 study of DMX-200 in Focal Segmental Glomerulosclerosis.
This first interim analysis of the ACTION3 trial showed that the drug had performed well based on the proteinuria efficacy endpoint of the study. This suggests that DMX-200 may result in improvement in kidney function when included in the standard of care in patients with FSGS.
Check out this recent interview with Dimerix as well!
Check our ASX buy/sell tips
